Olga Krystufkova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/506960/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. Rheumatology, 2021, 60, 1823-1831.	1.9	4
2	Interleukin-35 in idiopathic inflammatory myopathies. Cytokine, 2021, 137, 155350.	3.2	3
3	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. Scientific Reports, 2021, 11, 4719.	3.3	7
4	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. Clinical and Experimental Rheumatology, 2021, 39, 1021-1032.	0.8	1
5	Alterations in activin A–myostatin–follistatin system associate with disease activity in inflammatory myopathies. Rheumatology, 2020, 59, 2491-2501.	1.9	15
6	THU0365â€INCREASED HSP90 IN MUSCLE TISSUE AND PLASMA ASSOCIATES WITH DISEASE ACTIVITY AND SKELETAL MUSCLE INVOLVEMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. Annals of the Rheumatic Diseases, 2020, 79, 414.1-414.	0.9	0
7	OP0138â€CLUSTERIN ASSOCIATES WITH DISEASE MECHANISMS AND INFLAMMATION IN MYOSITIS PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 89.2-89.	0.9	0
8	Effect of CTLA4â€ŀg (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis. Scandinavian Journal of Immunology, 2019, 89, e12732.	2.7	8
9	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. Cytokine, 2019, 116, 13-20.	3.2	17
10	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. Rheumatology International, 2019, 39, 1037-1043.	3.0	6
11	THU0062â€THE DYSREGULATION OF NK CELLS AND NON-CLASSICAL AND CLASSICAL MONOCYTE SUBPOPULATIONS IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS. , 2019, , .		0
12	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases, 2018, 77, 30-39.	0.9	183
13	Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. Arthritis Research and Therapy, 2018, 20, 158.	3.5	23
14	08.01â€Heat shock protein 90 is increased in muscle tissue and plasma in idiopathic inflammatory myopathies. , 2017, , .		0
15	A9.02â€Heat shock protein 90 plasma levels correlate with disease activity, skeletal muscle, lung and heart involvement in idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2016, 75, A70.2-A71.	0.9	0
16	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	5.8	105
17	AB0599â€Interleukin-35 in Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2016, 75, 1109.2-1109.	0.9	0
18	SAT0240â€Snps in The Baff Gene Are Associated with Increased Risk of Anti-Jo-1-Positivity and High Serum	0.9	0

BAFF Levels in Patients with Myositis. Annals of the Rheumatic Diseases, 2016, 75, 755.2-755. 18

OLGA KRYSTUFKOVA

#	Article	IF	CITATIONS
19	Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. Clinical and Experimental Rheumatology, 2016, 34, 222-9.	0.8	2
20	A2.33â€Haplotype TTTT in the BAFF gene is associated with idiopathic inflammatory myopathies in HLA-DRB1*03 negative patients. Annals of the Rheumatic Diseases, 2015, 74, A29.2-A29.	0.9	0
21	Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. Journal of Clinical Investigation, 2015, 125, 4612-4624.	8.2	33
22	A1.48â€Enhanced expression of CD11c on non-classical CD16+peripheral blood monocytes in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A20.2-A21.	0.9	1
23	Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Research and Therapy, 2014, 16, 454.	3.5	25
24	FRI0520â€Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2014, 73, 575.3-576.	0.9	0
25	Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. Annals of the Rheumatic Diseases, 2012, 71, 71-74.	0.9	55
26	Anti-Ro52 epitope mapping in inflammatory myopathies. Annals of the Rheumatic Diseases, 2012, 71, A50.1-A50.	0.9	0
27	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine, 2011, 55, 116-121.	3.2	31
28	No Evidence for Linkage between the Hereditary Angiooedema Clinical Phenotype and the <i>BDKR1</i> , <i>BDKR2</i> , <i>ACE</i> or <i>MBL2</i> gene. Scandinavian Journal of Immunology, 2011, 74, 100-106.	2.7	13
29	The expression regulation of the HSPA1B gene in patients with myositis is not dependent on the presence of HLA-DRB1*03 risk allele. Annals of the Rheumatic Diseases, 2011, 70, A19-A20.	0.9	1
30	Serum levels of interferon do not correlate with disease activity in patients with dermatomyositis/polymyositis. Annals of the Rheumatic Diseases, 2011, 70, 879-880.	0.9	17
31	Receptors for B cell activating factor of the TNF Family (BAFF) are expressed in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies and correlate with plasmacytoid dendritic cell markers. Annals of the Rheumatic Diseases, 2011, 70, A64-A65.	0.9	0
32	Serum levels of IFN-Â do not correlate with disease activity in patients with dermatomyositis/polymyositis. Annals of the Rheumatic Diseases, 2011, 70, A89-A90.	0.9	0
33	Genetic variation in promoter sequence of B cell-activating factor gene is associated with increased risk of myositis development. Annals of the Rheumatic Diseases, 2010, 69, A31-A31.	0.9	0
34	Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2009, 68, 836-843.	0.9	95
35	Endogenous HLA–DR–restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint. Arthritis and Rheumatism, 2007, 56, 2150-2159.	6.7	21
36	The importance of cell surface RANKL in rheumatoid arthritis. Arthritis Research, 2005, 7, P152.	2.0	0

3

#	Article	IF	CITATIONS
37	Title is missing!. Arthritis Research, 2005, 7, P149.	2.0	0
38	Title is missing!. Arthritis Research, 2003, 5, 119.	2.0	0
39	Exon 1 polymorphism of the B2BKR gene does not influence the clinical status of patients with hereditary angioedema. Human Immunology, 2002, 63, 492-494.	2.4	20
40	Effect of intravenous immunoglobulins on in vitro immunoglobulin formation in patients with antibody immunodeficiency. Apmis, 2002, 110, 205-213.	2.0	2